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Ilya N. Kurochkinb and Rudy J. Richardsonc,d*ABSTRACT: The adult hen is the standard animal model for testing organophosphorus (OP) compounds for organophosphorus
compound-induced delayed neurotoxicity (OPIDN). Recently, we developed a mouse model for biochemical assessment of the
neuropathic potential of OP compounds based on brain neuropathy target esterase (NTE) and acetylcholinesterase (AChE)
inhibition. We carried out the present work to further develop the mouse model by testing the hypothesis that whole blood
NTE inhibition could be used as a biochemical marker for exposure to neuropathic OP compounds. Because brain NTE and AChE
inhibition are biomarkers of OPIDN and acute cholinergic toxicity, respectively, we comparedNTE and AChE 20-min IC50 values as
well as ED50 values 1h after single intraperitoneal (i.p.) injections of increasing doses of two neuropathic OP compounds that
differed in acute toxicity potency. We found good agreement between the brain and blood for in vitro sensitivity of each enzyme
as well for the ratios IC50(AChE)/IC50(NTE). Both OP compounds inhibited AChE and NTE in the mouse brain and blood dose-
dependently, and brain and blood inhibitions in vivo were well correlated for each enzyme. For both OP compounds, the ratio
ED50(AChE)/ED50(NTE) in blood corresponded to that in the brain despite the somewhat higher sensitivity of blood enzymes.
Thus, our results indicate that mouse blood NTE could serve as a biomarker of exposure to neuropathic OP compounds.
Moreover, the data suggest that relative inhibition of blood NTE and AChE provide a way to assess the likelihood that OP
compound exposure in a susceptible species would produce cholinergic and/or delayed neuropathic effects. Copyright © 2016
John Wiley & Sons, Ltd.
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Organophosphorus (OP) compounds covalently phosphylate
serine hydrolases, thus inhibiting their function. When this occurs
with neuropathy target esterase (EC 3.1.1.5, NTE), followed by an
aging process, a distal axonal degeneration ensues. This chemi-
cally induced neurodegenerative disease is known as organophos-
phorus compound-induced delayed neurotoxicity (OPIDN), and
OP compounds capable of producing this condition are termed
neuropathic. The aging process involves the formation of a nega-
tive charge on the organophosphyl moiety covalently attached
to the active site serine of NTE (Richardson et al., 2013).
If an OP compound is a substantially more potent inhibitor of
acetylcholinesterase (EC 3.1.1.7, AChE) than of NTE, then
cholinergic toxicity could result in lethality, thus obviating the
development of OPIDN. However, if the OP compound is
neuropathic, cholinergic toxicity may be mild, and sufficient
NTE can be inhibited and aged to initiate OPIDN (Lotti and
Moretto, 2005).
The OPIDN syndrome involves distal sensorimotor degeneration
of long large-diameter axons in the spinal cord and peripheral
nerves with associated sensory deficits and paralysis occurring
within 1–4weeks after exposure (Richardson and Makhaeva,
2014). Mechanistic research indicates that inhibition and aging of
>70% of NTE in neural tissue initiates OPIDN and that inactivation
of AChE is not involved ( Johnson, 1982; Lotti, 1992).J. Appl. Toxicol. 2016; 36: 1468–1475 Copyright © 2016 JohnThe neuropathic potential of an OP compound is its ability to
produce OPIDN. This tendency depends on its relative inhibitory
potency (RIP) towards NTE, the target for initiating OPIDN, and
AChE, the target for producing cholinergic toxicity. RIP is defined
here as IC50 (AChE)/IC50(NTE). By this definition, if the RIP is less than
one, then the compound is predicted to produce cholinergic toxic-
ity of sufficient severity that it cannot produce OPIDN at doses less
than the LD50. However, if the RIP is greater than one, then the
compound is predicted to produce OPIDN at doses less than the
LD50 (Lotti and Johnson, 1978; Richardson, 1992; Richardson et al.,
1993; Malygin et al., 2003; Wijeyesakere and Richardson, 2010).Wiley & Sons, Ltd.
PrDChVP diBu-PFP 
Figure 1. Structures of the test compounds.
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146The fact that an excellent correlation exists between
inhibition/aging of NTE just after exposure and the appearance
of OPIDN 1–4weeks later is sufficient to use this information for
the development of biomarkers and biosensors for delayed neuro-
pathic agents (Richardson et al., 2015). The discovery of blood NTE
in circulating lymphocytes and platelets (Dudek and Richardson,
1982; Richardson and Dudek, 1983; Bertoncin et al., 1985; Maroni
and Bleecker, 1986) enabled it to be used as a biomarker of animal
and human exposure to neuropathic OP compounds (Lotti, 1986,
1987; Lotti et al., 1983, 1986; Richardson and Dudek, 1983; Schwab
and Richardson, 1986). Furthermore, the development of sensitive
tyrosinase-based biosensors allowed us to measure NTE in whole
blood (Sigolaeva et al., 2001; Sokolovskaya et al., 2005). The biosen-
sor was used to establish correlations of NTE inhibitions in whole
blood with that in lymphocytes and the brain 24 h after dosing
hens with a neuropathic OP compound, O,O-dipropyl-O-
dichlorvinylphosphate (PrDChVP) (Makhaeva et al., 2003,
2007). These studies indicated that hen whole blood NTE can
be assayed and used as a biomarker of exposure to neuro-
pathic OP compounds (Sigolaeva et al., 2001; Makhaeva et al.,
2003, 2007; Sokolovskaya et al., 2005).
For decades, the adult female chicken (hen) has been the most
widely accepted in vivo model for the study of OPIDN and assess-
ment of the neuropathic potential of OP compounds (Ehrich and
Jortner, 2002). Standard laboratory rodents, mice and rats, have
been thought to be resistant to OPIDN because they do not readily
display clinical signs of hind limb paralysis despite the administra-
tion of high doses of neuropathic compounds (Abou-Donia, 1981;
Veronesi et al., 1991). However, more detailed investigations
showed that although mice and rats are resistant to clinical signs
of ataxia and paralysis, they are susceptible to axonal lesions
following neuropathic OP compound exposure. Moreover, the
severity of structural damage to long axons in the spinal cord of
rats and mice has been shown to correlate with the extent of
NTE inhibition (Veronesi, 1984; Padilla and Veronesi, 1985; Mutch
et al., 1995; Read et al., 2009, 2010).
Recently, we demonstrated that NTE from mouse and hen
brain exhibits similar sensitivity to neuropathic OP compounds
in vitro. Excellent correlations were obtained for inhibition
kinetics in vitro of mouse brain enzymes vs. hen brain enzymes.
Furthermore, inhibition of mouse brain AChE and NTE after
dosing with OP compounds afforded ED50 ratios that agreed
with RIP values assessed in vitro. Thus, mouse brain NTE and
AChE could be used for biochemical assessment of the
neuropathic potential of OP compounds both in vitro and
in vivo (Makhaeva et al., 2014).
We undertook the present work as a further development of the
mousemodel for biochemical assessment of the ability of OP com-
pounds to produce OPIDN. Our aims were twofold: (i) to investi-
gate using mouse whole blood NTE as a biochemical marker for
exposure to neuropathic OP compounds; and (2) to study the pos-
sibility of employing comparisons of NTE and AChE inhibition in
mouse whole blood for assessing the risk of OPIDN in susceptible
species exposed to neuropathic OP compounds.
We carried out these aims using two neuropathic OP com-
pounds: O,O-di-1-propyl-O-2,2-dichlorvinyl phosphate (PrDChVP)
and O,O-di-1-butyl-O-(1-trifluoromethyl-2,2,2-trifluoroethyl) phos-
phate (diBu-PFP) (Fig. 1) that differed in potency for producing
acute cholinergic toxicity. PrDChVP has high acute cholinergic tox-
icity as well as a rather high neuropathic potential. It is a known
neuropathic agent (Lotti and Johnson, 1978, Makhaeva et al.,
1995). In contrast, although diBu-PFP has a high neuropathicJ. Appl. Toxicol. 2016; 36: 1468–1475 Copyright © 2016 Johnpotential in vitro and in vivo, it exhibits very low acute cholinergic
toxicity as we have shown previously (Makhaeva et al., 2008,
2009, 2014). We compared their inhibitory activities against mouse
brain and blood AChE and NTE in vitro and in vivo 1h after a single
intraperitoneal (i.p.) administration of increasing doses of the com-
pounds. In order to evaluate the possibility of using mouse blood
enzymes for OPIDN risk assessment in vivo, we examined correla-
tions between brain and blood inhibition of AChE and NTE pro-
duced by each compound. The ED50 values were determined
from dose–response curves for mouse blood and brain AChE and




S-Acetylthiocholine iodide, ethopropazine hydrochloride and
5,5′-dithiobis(2-nitrobenzoic acid) were purchased from
Sigma-Aldrich Co. (Steinheim, Germany). Phenyl valerate (PV),
N,N′-di-2-propylphosphorodiamidofluoridate (mipafox, MIP),
O,O-di-1-propyl O-2,2-dichlorovinyl phosphate (PrDChVP) and
O,O-di-1-butyl-O-(1-trifluoromethyl-2,2,2-trifluoroethyl) phos-
phate (diBu-PFP) were synthesized and characterized in the In-
stitute of Physiologically Active Compounds, Russian Academy
of Sciences (IPAC, RAS, Chernogolovka, Russia). Synthesis of
diBu-PFP is described by Makhaeva et al. (2008, 2009). The
purity of all substances produced by IPAC, RAS was >99% by
spectral and chromatographic analysis data. O,O-Diethyl-4-ni-
trophenyl phosphate (paraoxon, PO) and protein standard
(BSA) were from Sigma Chemical Co. (St. Louis, MO, USA).
Poly(N,N-dimethylaminoethyl methacrylate), PDMAEMA1600
(where the subscript denotes the number-average degrees of
polymerization) with a molecular weight of 250 000 g mol1
and a polydispersity index of 2 was synthesized and character-
ized according to (Plamper et al., 2007; Steinschulte et al., 2012)
and provided by Dr. Felix A. Plamper (RWTH Aachen University,
Germany). All other chemicals were analytical grade and used
without further purification. Aqueous solutions were prepared
using deionized water.Tyrosinase biosensor fabrication
Tyrosinase biosensors were fabricated according to the ap-
proaches described in (Sigolaeva et al., 2013a, 2014a) and used
for the assay of NTE activity in blood. To fabricate tyrosinase bio-
sensors, screen-printed electrodes (SPEs) were printed on poly(vi-
nyl chloride) substrates of 0.2mm thickness by means of
conductive graphite paste (Gwent, UK) using a 200 mesh screen
stencil. Each SPE consisted of a round-shaped working area
(2.5mm diameter), a conductive track (30×1.5mm), and a square
extremity (3× 7mm) for electrical contact. The 5 g l1 solution of
PDMAEMA1600 was prepared in 50mM sodium phosphate, pH9.
Tyrosinase was prepared in 12.5g l1 concentration in 10mM Tris,Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jat
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1470pH7, immediately before the experiments. The PDMAEMA1600 was
adsorbed onto SPEs by covering the working area of each SPE
using a 10-μl drop of the PDMAEMA1600 solution, followed by 1h
adsorption. After that time, the SPEs were rinsed with Milli-Q water
and dried using a stream of air. The tyrosinase was adsorbed in a
similar way for 10min, followed by rinsing with Milli-Q water and
drying with a stream of air. Tyrosinase biosensors were stored at
4°C until further use. Electrochemical experiments were performed
at an ambient temperature in a one-compartment electrochemical
cell with stirring (volume of 1ml) in 0.05M sodium phosphate
buffer with 0.1M NaCl, pH7.0. A two-electrode configuration was
used, where an SPE covered by PDMAEMA1600/tyrosinase films
with an active surface area of 0.049 cm2 served as the working
electrode and Ag/AgCl (length 1 cm, diameter 3mm, and surface
area 1.03 cm2) was used as a reference electrode. A potentiostat
IPC-Micro (Kronas Ltd., Moscow, Russia) used for electrochemical
measurements was interfaced with a desktop computer and elec-
trochemical parameters were controlled by the potentiostat soft-
ware furnished with the instrument.Animals
All experiments with animal subjects were carried out accord-
ing to protocols for the use and care of laboratory animals ap-
proved by the Institute of Physiologically Active Compounds,
RAS (Chernogolovka, Russia). Adult outbred male CD-1 albino
mice (20–24 g, 2months of age) (Kennel Pushchino, Pushchino,
Russia) were used. Mice were housed 6–8 per plastic shoebox
cage at 22–24°C and fed mouse chow (Purina, St Louis, MO,
USA; or Agro-range Ltd, Sergiev Posad, Russia) and tap water
ad libitum.Preparation of brain and blood tissue for neuropathy target
esterase and acetylcholinesterase assays
Animals were euthanized via CO2 asphyxiation. The brains were
immediately removed, weighed and frozen in liquid nitrogen; they
were stored at 70°C until use. The thawed brain samples were
homogenized at 4 °C in five volumes of buffer (50mM Tris–HCl,
0.2mM EDTA, pH8.0) with a Potter homogenizer. The homoge-
nates were centrifuged for 15min at 9000×g at 4 °C to prepare
the 9S supernatant used for enzyme assay (Padilla and Veronesi,
1985). Aliquots of the supernatants (brain 9S fraction) were stored
at70°C until use. Mouse blood was obtained following decapita-
tion after killing via CO2-induced asphyxiation. Trunk blood from
each animal was collected immediately in glass vials containing
citrate anticoagulant (3.8% w/v sodium citrate; 0.2ml of citrate
per ml of blood). All blood samples were aliquoted, frozen in liquid
nitrogen and stored at 70°C before use. For the preparation of
whole blood hemolysates, thawed blood samples were diluted
1/100 (v/v) in the appropriate diluting buffer (see below for buffer
for each esterase) at 4 °C. After careful stirring for 2min, the hemo-
lyzed blood samples were aliquoted into 15-ml polypropylene
screw-cap tubes, immediately frozen in liquid nitrogen to ensure
complete hemolysis and stored at20°C until use. Before analysis,
the samples were thawed slowly in an ice-water bath.Acetylcholinesterase assay
AChE activity in the brain and whole blood was determined in 9S
brain supernatants and 1/100 (v/v) blood hemolysates prepared
in 0.1M sodium phosphate pH7.5. Assays were carried out usingCopyright © 2016 Johnwileyonlinelibrary.com/journal/jatthe Ellman spectrophotometric method (Ellman et al., 1961) with
modifications. Incubations were carried out in 0.1M Na/K
phosphate pH7.5 at 37°C with 1mM acetylthiocholine iodide as
a substrate in the presence of a selective inhibitor of BChE,
ethopropazine (0.02mM, 10min preincubation), for elimination
of BChE activity (Padilla et al., 1999; Worek et al., 1999; Reiner
et al., 2004).
For the AChE assay in hemolyzed blood, the standard Ellman
assay wavelength of 412 nm was changed to 436 nm
(ε436 = 10600M
1 cm1) to reduce interference from the high
absorbance of hemoglobin (Worek et al., 1999). All data were
automatically corrected for spontaneous hydrolysis of the
substrate by carrying out absorbance measurements simulta-
neously in sample and reference cuvettes (3-ml volume, 1-cm
path length) at 37°C using a Gilford-250 spectrophotometer.Neuropathy target esterase assay
Brain NTE activity was determined in 9S supernatants by the color-
imetric method of Johnson ( Johnson, 1977) with slight modifica-
tions (Kayyali et al., 1991; Makhaeva et al., 2003). All reactions
were carried out at 37°C for the entire assay. 9S supernatant
(50 μl) was diluted in 50mM Tris–HCl, 0.1mM EDTA, pH 8.0 at
37°C. The suspension containing NTE along with other serine
esterases was preincubated for 20min with 50 μM PO (final
concentration in 500 μl total volume) to inhibit background
esterase activity, and paired samples were preincubated for
20min with 50 μM PO and 250 μM MIP (final concentrations
in 500 μl total volume) to completely inhibit NTE activity
(Padilla and Veronesi, 1985). Thus, after adding substrate (PV),
the difference in esterase activity between these two
preincubation conditions corresponded to NTE activity. The
preincubation was stopped by adding the substrate solution
(500 μl) of 2.8mM PV/N,N′-dimethylformamide (PV/DMF) in
0.03% (w/v) Triton X-100, and the reaction was allowed to pro-
ceed for 20min, during which PV was hydrolyzed to produce
phenol. A stop solution (500 μl) of 1% (w/v) sodium dodecyl sul-
fate (SDS)/0.025% (w/v) 4-aminoantipyrine (4-AAP) was added,
and the reaction of 4-AAP with the phenol produced was allowed
to proceed for 5min. The chromophore was produced by adding
250 μl of 0.4% (w/v) K3Fe(CN)6, and the color was allowed to
develop and stabilize for 10min. The endpoint absorbance was
measured at 486nm (ε486 = 16470M
1min1) using a Bio-Rad
Benchmark Plus microplate reader (Marnes-la-Coquette, France).
Blood NTE activity was determined in 1/100 (v/v) blood
hemolysates according to the differential inhibition method
of Johnson (Johnson, 1977) with an electrochemical endpoint
as described previously (Sigolaeva et al., 2001, 2013b;
Makhaeva et al., 2003). Briefly, 1/100 (v/v) blood hemolysate
samples (300 μl) were preincubated for 20min at 37°C in
50mM Tris–HCl/0.2mM EDTA (pH 8.0 at 37°C) with 50 μM PO
(sample B) or 50 μM PO plus 250 μM MIP (sample C) (final
inhibitor concentrations in a final volume of 400 μl). The PV
substrate was added (in a final apparent concentration of
0.54mM and final volume of 500 μl), and the incubation was
continued for the next 40min at 37°C. The reaction was
stopped by addition of 100 μl of 1% (w/v) aqueous SDS. The
released phenol was assayed amperometrically after 20- to
50-fold dilution of samples in 50mM sodium phosphate with
100mM NaCl, pH 7.0. The analytical signal was determined as
the value of steady-state baseline current change (the differ-
ence between an average value of steady-state baselineJ. Appl. Toxicol. 2016; 36: 1468–1475Wiley & Sons, Ltd.
Mouse blood neuropathy target esterase biomarkercurrent before and after analyte addition). Activity values were
calculated using phenol calibration curves, obtained under the
same conditions, and each was corrected for spontaneous hy-
drolysis of the substrate, determined separately. NTE activity
was calculated as the difference in the amount of phenol re-
leased between samples B and C.In vitro inhibition of acetylcholinesterase and neuropathy
target esterase in mouse brain and blood preparations
For measurement of NTE and AChE inhibition in vitro, pooled
samples of mouse brain and blood were used. Stock solu-
tions of the test compounds (PrDChVP and diBu-PFP) in a
water-miscible organic solvent (DMSO) were serially diluted
to appropriate working concentrations so that the final
organic solvent concentration in the incubation mixture was
≤1% (v/v), a concentration range previously shown to have
no significant effect on enzyme activity. The IC50 values for
the test compounds against brain and blood NTE and AChE
were determined by 20-min incubation of mouse brain and
blood samples with 10 to 12 different concentrations of
either PrDChVP (from 1011 M to 105 M) or diBu-PFP (from
1011 M to 104 M) in working buffer. For NTE, test inhibitors
were added at the end of the first preincubation interval with
PO or PO+MIP, and inhibition was continued for 20min before
addition of PV substrate (Kropp and Richardson, 2003). Residual
NTE and AChE activities in brain and blood preparations were
measured as described above.In vivo inhibition of acetylcholinesterase and neuropathy
target esterase in mouse brain and blood
PrDChVP and diBu-PFP were dissolved in DMSO and injected once,
i.p., in a volume of 0.1ml in increasing doses: 0.75, 1.5, 3, 6, 12, 24
and 36mgkg1 for PrDChVP and 0.5, 1, 2.5, 15, 30, 100, 250, 1000
and 2000mgkg1 for diBu-PFP. At least six animals were used for
each dose. Because of the high cholinergic toxicity of PrDChVP,
mice in this group were pretreated with atropine sulfate 20min
before PrDChVP injection (20mgkg1 in water, i.p.); in this case,
the control animals received atropine sulfate and DMSO. In the ex-
periment with diBu-PFP, the control animals were dosed only with
DMSO. After 1 h, themice were decapitated under CO2 anesthesia.
Preparation of brain and blood samples and assay methods for
AChE and NTE are described above.Protein assay
Protein was assayed by the Coomassie blue dye-binding method,
with BSA as a standard (Bradford, 1976).147Statistical analyses
Data are expressed as the mean±SEM. Plots, linear correlations,
and dose–response curve fitting were carried out using Origin
6.1 for Windows, OriginLab (Northampton, MA, USA). Independent
t-tests were carried out using GraphPad Prism 6.05 for Windows,
GraphPad Software (San Diego, CA, USA). The level of significance
was set at P< 0.05.J. Appl. Toxicol. 2016; 36: 1468–1475 Copyright © 2016 JohnResults
Inhibition of acetylcholinesterase and neuropathy target
esterase by PrDChVP and diBu-PFP in mouse brain and
blood in vitro
Table 1 shows the experimental 20-min IC50 values for OP inhibi-
tors PrDChVP and diBu-PFP against AChE and NTE from mouse
brain and whole blood. PrDChVP had similar IC50 values across
the two tissues for each enzyme (blood/brain ratios of 1.26 for
AChE and 1.01 for NTE), whereas diBu-PFP IC50 values were sub-
stantially higher in the blood (blood/brain ratios of 3.16 for AChE
and 3.44 for NTE). The RIP values were greater than one in each
case, indicating that both compounds would be expected to be
neuropathic (Wijeyesakere and Richardson, 2010). Of particu-
lar interest is the fact that for each compound, the brain and
blood RIP values were not significantly different from each
other (t-test, P> 0.05).Inhibition of acetylcholinesterase and neuropathy target
esterase by PrDChVP and diBu-PFP in mouse brain and
blood in vivo
Inhibition of NTE and AChE in mouse brain and blood was deter-
mined 1h after i.p. administration of increasing doses of each of
the two test OP compounds, PrDChVP and diBu-PFP. The data ob-
tained from these in vivo experiments are shown in Fig. 2. As can
be seen, both PrDChVP and diBu-PFP inhibited NTE and AChE in
mouse brain and blood in a dose-dependent manner. Moreover,
over the linear ranges of the dose–response curves, there were
strong correlations between brain and blood inhibitions for each
enzyme and each compound (Fig. 3).
By analyzing the dose–response curves in Fig. 2, the ED50
values for inhibition of AChE and NTE in mouse brain and
blood by PrDChVP and diBu-PFP were obtained, and the ratios
ED50(AChE)/ED50(NTE) were calculated as shown in Table 2.
This ratio for brain enzymes in vivo can be considered a
counterpart of the in vitro RIP (Richardson, 1992; Malygin
et al., 2003). Accordingly, in agreement with our results for
the in vitro RIP values, the ED50 ratios for each compound
were greater than one, again indicating that the compounds
would be expected to be neuropathic. Moreover, for each
compound, there was no significant difference between brain
and blood ED50 ratios (t-test; P> 0.05).Discussion
The results of the present study support our hypothesis that
mouse blood NTE could serve as a biochemical marker of exposure
to neuropathic OP compounds and that relative inhibition of AChE
and NTE in mouse blood could be used to assess the risk of OPIDN
in susceptible species that might be exposed to neuropathic OP
compounds.
The OP compounds selected for this investigation were
PrDChVP and diBu-PFP (Fig. 1). PrDChVP produces OPIDN in hens
with a minimal neuropathic dose of 0.6mgkg1 (Lotti and
Johnson, 1978; Makhaeva et al., 1995). It has a rather high neuro-
pathic potential with an RIP first reported to be 2.6 (Lotti and John-
son, 1978), inmore recent work as 3.47 (Makhaeva et al., 2014), and
in the present study as 3.89 (brain) and 4.80 (blood). In addition,
PrDChVP has high acute toxicity, with an LD50 of 10mgkg
1 in
hens (Albert and Stearns, 1974) and 15mgkg1 in miceWiley & Sons, Ltd. wileyonlinelibrary.com/journal/jat
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Table 1. Twenty-minute IC50 values and relative inhibitor potencies (RIP) for organophosphorus (OP) inhibitors against acetylcholin-
esterase (AChE) and neuropathy target esterase (NTE) from preparations of mouse brain and blood a
Inhibitor Brain IC50, nM Blood IC50, nM RIP = IC50(AChE)/IC50(NTE)
AChE NTE AChE NTE Brain Blood
PrDChVP 97.6± 6.4 25.1±2.1 123±4 25.4 ± 2.5 3.89± 0.34 4.80± 0.49
diBu-PFP 494±29 66.3±4.1 1560±120 228±17 7.45± 0.64 6.80± 0.73
a Values are the mean±SEM (n=3) from determinations on mouse brain 9S supernatants and mouse whole blood hemolysates.
Figure 2. Dose-related neuropathy target esterase (NTE) and acetylcholinesterase (AChE) inhibition in brain and blood of mice given O,O-dipropyl-
O-dichlorvinylphosphate (PrDChVP) (A, B) and O,O-di-1-butyl-O-(1-trifluoromethyl-2,2,2-trifluoroethyl) phosphate (diBu-PFP) (C, D) 1 h after dosing
intraperitoneally (i.p.). Results are % control (mean ± SEM; n = 5 to 6). Control brain, nmol/(min ×mg protein): AChE =74.4 ± 4.0 (n = 10); NTE = 14.5
± 0.36 (n = 8). Control blood, nmol/(min ×ml blood): AChE = 829 ± 35 (n = 18), NTE = 18 ± 2 (n = 8).
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1472(Makhaeva et al., 2014). PrDChVP was intensively studied in our
previous experiments in vitro and in vivo in hens and rats
(Makhaeva et al., 1995, 2003, 2007). Moreover, we previously
used PrDChVP as a known neuropathic agent to develop a
mouse model for biochemical assessment of neuropathic po-
tential (Rudakova et al., 2012; Makhaeva et al., 2014). Thus, in
the current investigation, PrDChVP was used with high confi-
dence as a compound with both high neuropathic potential
and high cholinergic toxicity to investigate NTE and AChE in-
hibition in mouse blood compared with inhibition of these
enzymes in mouse brain.
The second compound used in the present study was diBu-PFP.
In our preliminary experiments in vitro, diBu-PFP exhibited a high
neuropathic potential with an RIP of 4.99 (Makhaeva et al., 2008,
2009). More recently, we further evaluated diBu-PFP for inhibition
ofmouse brain NTE and AChE in vitro and in vivo, confirming its high
neuropathic potency (Rudakova et al., 2012; Makhaeva et al., 2014).
This trend was borne out in the present study with an RIP of 7.45
(brain) and 6.80 (blood). However, in contrast to PrDChVP, diBu-
PFP has low acute toxicity, with an LD50 (i.p.) inmice>2000mgkg
1
(Makhaeva et al., 2014; Rudakova et al., 2013).Copyright © 2016 Johnwileyonlinelibrary.com/journal/jatAChE (Massoulié et al., 2008) andNTE (Moser et al., 2000) are each
encoded by their single respective genes in mammals (including
humans and mice), and the molecular forms of each enzyme
expressed in different tissue compartments such as brain and
blood have identical or highly similar intrinsic responses to inhibi-
tors (Vose et al., 2008; Herkert et al., 2012). However, when certain
extrinsic factors are present, such as other enzymes that bind or hy-
drolyze OP inhibitors, inhibitory potency will appear to decrease
(i.e. IC50 values will increase) as demonstrated for chlorpyrifos oxon
against rat brain AChE in the presence or absence of plasma or liver
homogenate (Chanda et al., 1997; Mortensen et al., 1998).
Whereas the apparent inhibitory potency of PrDChVP against
brain enzymes was similar to that against blood enzymes, this
was not the case for diBu-PFP, which exhibited lower apparent in-
hibitory potency against blood enzymes than it did against brain
enzymes (Table 1). The reasons for the lower apparent potency
of diBu-PFP toward blood AChE and NTE were not directly
evaluated in the present study. However, given the higher hydro-
phobicity of diBu-PFP and higher potency toward serum
carboxylesterase and butyrylcholinesterase compared with AChE
and NTE (Makhaeva et al., 2008), the concentration of diBu-PFPJ. Appl. Toxicol. 2016; 36: 1468–1475Wiley & Sons, Ltd.
Figure 3. Correlations between brain and blood inhibition 1 h after dosing mice with O,O-dipropyl-O-dichlorvinylphosphate (PrDChVP): (A) neuropathy
target esterase (NTE); (B) acetylcholinesterase (AChE). Correlations between brain and blood inhibition 1 h after dosing mice with O,O-di-1-butyl-O-(1-
trifluoromethyl-2,2,2-trifluoroethyl) phosphate (diBu-PFP): (C) NTE; (D) AChE.
Table 2. ED50 values of organophosphorus (OP) compounds against acetylcholinesterase (AChE) and neuropathy target esterase
(NTE) in mouse brain and blood 1h after intraperitoneal (i.p.) dosing and calculated ED50 ratios
a
Brain ED50, mg/kg Blood ED50, mg/kg ED50(AChE)/ED50(NTE)
Compound AChE NTE AChE NTE Brain Blood
PrDChVP 4.06±0.09 1.92± 0.16 4.0 ± 0.12 2.01± 0.11 2.1 ± 0.18 2.0 ± 0.13
diBu-PFP 499.4±53.8 121.61± 3.45 154.4± 4.9 36.1 ± 1.27 4.1 ± 0.45 4.3 ± 0.20
a Values are the mean±SEM (n=5 to 6). ED50 values were determined from analyses of dose–response curves in Fig. 2. Brain assays
were carried out with 9S supernatants from mouse brain homogenates. Blood assays were carried out with mouse whole blood
hemolysates.
Mouse blood neuropathy target esterase biomarker
147could have been preferentially lowered because of binding to
these enzymes as well as to serum albumin (Duysen et al., 2012;
Tarhoni et al., 2008). In addition, serumparaoxonase (PON1) hydro-
lyzes a number of OP compounds (Costa et al., 2003), and it is pos-
sible that diBu-PFP is a better substrate than PrDChVP for serum
paraoxonase1 (PON1), a hypothesis to be tested in future work.
Despite the differential response of blood enzymes to the two
inhibitors, the brain and blood RIP values were not statistically dif-
ferent from each other for each inhibitor (Table 1). This is to be ex-
pected, because if the concentration of diBu-PFP were decreased
in blood, the consequent increase in IC50 between brain and blood
should be similar for AChE and NTE; in fact, the observed fold
increases were 3.16 (AChE) and 3.44 (NTE). Thus, these differ-
ences would nearly cancel when the RIP values were calcu-
lated. In any event, for both compounds, the brain and blood
RIP values are in agreement and the fact that these ratios areJ. Appl. Toxicol. 2016; 36: 1468–1475 Copyright © 2016 Johngreater than one is consistent with the known neuropathic po-
tential of these compounds (Wijeyesakere and Richardson,
2010; Makhaeva et al., 2014).
Just as blood AChE inhibition has been recommended and
employed as a surrogate for brain AChE inhibition and a bio-
marker of exposure to cholinergic OP compounds (Carlock
et al., 1999; Chen et al., 1999), we hypothesized that inhibition
of mouse blood NTE reflects brain NTE inhibition and serves
as a biochemical marker of exposure to neuropathic OP com-
pounds, as demonstrated for inhibition of NTE in hen and
human blood (Lotti, 1986; Makhaeva et al., 2003). These ex-
pectations were confirmed by our results, which showed
dose-related increases in AChE and NTE inhibition (Fig. 2) that
were highly correlated between brain and blood (Fig.3).
However, as summarized in Table 2, whereas the ED50 values
for PrDChVP were the same for respective brain and bloodWiley & Sons, Ltd. wileyonlinelibrary.com/journal/jat
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1474enzymes, these values for diBu-PFP were higher in the brain
by a factor of 3.23 for AChE and 3.37 for NTE. The differences
between in vivo sensitivities of brain and blood enzymes to
diBu-PFP were of similar magnitude to the observed differ-
ences in vitro but in the opposite direction. Such apparent
paradoxes are not unusual. As pointed out by Chanda et al.
(1997), the pattern of inhibition of esterases in vivo can be
quite different from what is seen in vitro. Moreover, the phar-
macokinetic factors governing such differences will, in general,
be highly compound-specific (Maxwell, 1992). Nevertheless, in
a similar manner to the cancellation of systematic differences
between brain and blood IC50 values when RIP ratios were cal-
culated (Table 1), the same behavior was seen with systematic
differences between brain and blood ED50 values when these
ratios were calculated (Table 2). As was the case for RIP values
based on IC50 ratios, the ED50 ratios for each compound were
the same for brain and blood enzymes. Moreover, the ratios
were greater than one, consistent with the known neuropathic
potential of the compounds (Wijeyesakere and Richardson,
2010; Makhaeva et al., 2014).
In conclusion, the data presented and discussed above allow us
to consider mouse blood NTE as a biochemical marker of exposure
to neuropathic OP compounds. Moreover, inhibition of NTE in the
blood can be used in conjunction with inhibition of blood AChE to
assess the likelihood that an exposure of a susceptible species to
an OP compound would produce cholinergic and/or delayed
neuropathic effects.
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